A Study of LY2940680 in Japanese Participants With Advanced Cancers

NCT01919398 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm Metastasis

Interventions

DRUG: LY2940680

Sponsor

Eli Lilly and Company